Financials Anhui Anke Biotechnology (Group) Co., Ltd.

Equities

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 06/05/2024 am IST			5-day change	1st Jan Change
10.48 ^CNY	+2.54%		+5.12%	+2.54%

25/04	Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
28/03	Anhui Anke Biotechnology Co., Ltd. Proposes Final Dividend for 2023	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	15,849	20,044	21,448	15,623	17,094	17,529	-	-
Enterprise Value (EV) ¹	15,849	20,044	21,448	15,623	17,094	18,259	17,529	17,529
P/E ratio	126 x	56.5 x	101 x	21.8 x	20 x	17.8 x	15 x	-
Yield	0.99%	1.36%	-	-	-	-	-	-
Capitalization / Revenue	9.25 x	11.8 x	-	6.7 x	5.97 x	4.81 x	4.14 x	-
EV / Revenue	9.25 x	11.8 x	-	6.7 x	5.97 x	5.01 x	4.14 x	-
EV / EBITDA	68.4 x	40.5 x	-	16.9 x	16.8 x	14.2 x	11.7 x	-
EV / FCF	141 x	-	-	68.5 x	22.6 x	15.2 x	14.9 x	9.71 x
FCF Yield	0.71%	-	-	1.46%	4.43%	6.57%	6.73%	10.3%
Price to Book	6.03 x	7.07 x	-	-	-	-	-	-
Nbr of stocks (in thousands)	16,38,499	16,38,466	16,38,466	16,69,071	16,72,639	16,72,639	-	-
Reference price ²	9.673	12.23	13.09	9.360	10.22	10.48	10.48	10.48
Announcement Date	28/02/20	07/04/21	30/03/22	27/03/23	27/03/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	1,713	1,701	-	2,331	2,866	3,645	4,237	-
EBITDA ¹	231.7	494.3	-	924.8	1,020	1,283	1,501	-
EBIT ¹	165.2	424	-	842	924	1,170	1,380	1,658
Operating Margin	9.64%	24.92%	-	36.12%	32.24%	32.1%	32.57%	-
Earnings before Tax (EBT) ¹	163.4	416.1	-	833.8	919.9	1,174	1,392	1,683
Net income ¹	124.5	359	206.6	703.3	847.2	990	1,174	-
Net margin	7.27%	21.1%	-	30.17%	29.56%	27.16%	27.71%	-
EPS ²	0.0769	0.2167	0.1300	0.4300	0.5100	0.5900	0.7000	-
Free Cash Flow ¹	112.4	-	-	228.2	757.9	1,200	1,180	1,806
FCF margin	6.56%	-	-	9.79%	26.45%	32.92%	27.85%	-
FCF Conversion (EBITDA)	48.52%	-	-	24.68%	74.33%	93.53%	78.61%	-
FCF Conversion (Net income)	90.3%	-	-	32.45%	89.45%	121.21%	100.51%	-
Dividend per Share	0.0962	0.1667	-	-	-	-	-	-
Announcement Date	28/02/20	07/04/21	30/03/22	27/03/23	27/03/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	730	-	-
Net Cash position ¹	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	0.569 x	-	-
Free Cash Flow ¹	112	-	-	228	758	1,200	1,180	1,806
ROE (net income / shareholders' equity)	5.2%	13.3%	-	23.8%	24.9%	37%	56.2%	-
ROA (Net income/ Total Assets)	4.33%	10.7%	-	16.5%	-	26.8%	35.6%	-
Assets ¹	2,876	3,365	-	4,255	-	3,694	3,298	-
Book Value Per Share	1.600	1.730	-	-	-	-	-	-
Cash Flow per Share	0.1800	0.2800	-	-	-	-	-	-
Capex ¹	183	138	-	471	195	166	444	120
Capex / Sales	10.7%	8.12%	-	20.2%	6.81%	4.55%	10.48%	-
Announcement Date	28/02/20	07/04/21	30/03/22	27/03/23	27/03/24	-	-	-

¹CNY in Million

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

D+

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.48 CNY

Average target price

19.54 CNY

Spread / Average Target

+86.45%

	1st Jan change	Capi.
ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD.	+2.54%	2.36B
CSL LIMITED	-3.16%	88.14B
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-14.43%	31.67B
UCB	+51.20%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.85%	15.65B
INCYTE CORPORATION	-13.87%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-7.87%	11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-39.40%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+5.62%	8.81B